Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.

Read full article (External website)

1 reply

Trackbacks & Pingbacks

  1. […] post Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply